Patients with InsomniaPhase 3NCT05461352
Long-Term Study of TS-142 in Patients with Insomnia
A Phase 3 study testing TS-142 5 mg and TS-142 10 mg in people with Patients with Insomnia, run by Taisho Pharmaceutical Co., Ltd. at 1 site in Japan.
Trial summary
This is a randomized, open-label, multi-center long-term study in patients with insomnia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Patients with Insomnia
- What is being tested?
- TS-142 5 mg and TS-142 10 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 401 participants
- Where
- 1 siteJapan
- Study dates
- 11 Oct 2022to 7 Mar 2024
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Japanese male and female who are aged 18 years or older at the time of informed consent
- Outpatients
- Patients falling under the category of insomnia disorder according to the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)
- Other protocol defined inclusion criteria could apply.
Who cannot join
- Patients falling under the category of any disorders other than insomnia disorder among sleep-wake disorders according to the diagnostic criteria in DSM-5
- Patients with psychiatric diseases other than depression and anxiety
- Patients with symptoms such as pain, pruritus, frequent urination and asthma that seriously prevent their sleep
- Other protocol defined exclusion criteria could apply.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Multi-center, Open-label Long-Term Study of TS-142 in Patients with Insomnia Disorder
This is a randomized, open-label, multi-center long-term study in patients with insomnia.
- Conditions
- Patients with Insomnia
- Being tested
- TS-142 5 mg, TS-142 10 mg
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TS-142 5 mgDrug
Participants received repeated doses of 5 mg of TS-142 (oral tablet)
TS-142 10 mgDrug
Participants received repeated doses of 10 mg of TS-142 (oral tablet)
| Study group | Role | What they receive |
|---|---|---|
| 5 mg | Experimental | Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime Receives: Drug: TS-142 5 mg |
| 10 mg | Experimental | Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime Receives: Drug: TS-142 10 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events
To evaluate the Long-term safety of TS-142 in patients with insomnia
Measured: From start of investigational drug administration to final test and observation; up to approximately 1 year
Secondary outcomes (5)
Mean change from baseline of subjective sleep latency (sSL)
sSL defined as the duration of time that it took to fall asleep as recorded in a sleep diary.
Measured: From baseline up to Week 52
Mean change from baseline of subjective sleep efficacy (sSE)
sSE is defined as the percentage of total sleep time (TST) in total amount of time from bedtime to wake-up time in a sleep diary.
Measured: From baseline up to Week 52
Mean change from baseline of subjective total sleep time (sTST)
sTST defined as the total amount of time spent asleep before wake-up time as recorded in a sleep diary.
Measured: From baseline up to Week 52
Mean change from baseline of subjective wake time after sleep onset (sWASO)
sWASO is defined as the total amount of time spent awake after falling asleep and before wake-up time as recorded in a sleep diary.
Measured: From baseline up to Week 52
Mean change from baseline of subjective number of awakenings (sNAW)
sNAW is defined as the total number of awaking after falling asleep and before getting out of bed as recored in a sleep diary
Measured: From baseline up to Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2022
- Study start11 Oct 2022
- Primary completion7 Mar 2024
- Study completion7 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients with InsomniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 401 participants (actual)
Sponsor and investigators
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Taisho Director, Study director, Taisho Pharmaceutical Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05461352
- Sponsor's protocol ID
- TS142-302
- Status last verified
- Mar 2024
- First submitted
- 7 Jul 2022
- Last updated
- 28 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Open-label Long-Term Study of TS-142 in Patients with Insomnia Disorder
- ClinicalTrials.gov ID
- NCT05461352
- Acronym / sponsor ID
- TS142-302
- Conditions
- Patients with Insomnia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 401 participants (actual)
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 11 Oct 2022 (actual)
- Primary completion
- 7 Mar 2024 (actual)
- Study completion
- 7 Mar 2024 (actual)
- First posted
- 18 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, open-label, multi-center long-term study in patients with insomnia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 5 mg | Experimental | Drug: TS-142 5 mgPeriod in which participants received repeated doses of 5 mg TS-142 prior to bedtime |
| 10 mg | Experimental | Drug: TS-142 10 mgPeriod in which participants received repeated doses of 10 mg TS-142 prior to bedtime |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Japanese male and female who are aged 18 years or older at the time of informed consent
- Outpatients
- Patients falling under the category of insomnia disorder according to the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)
- Other protocol defined inclusion criteria could apply.
Key exclusion criteria (4 listed)
- Patients falling under the category of any disorders other than insomnia disorder among sleep-wake disorders according to the diagnostic criteria in DSM-5
- Patients with psychiatric diseases other than depression and anxiety
- Patients with symptoms such as pain, pruritus, frequent urination and asthma that seriously prevent their sleep
- Other protocol defined exclusion criteria could apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TS-142 5 mgParticipants received repeated doses of 5 mg of TS-142 (oral tablet) | Drug | 5 mg |
| TS-142 10 mgParticipants received repeated doses of 10 mg of TS-142 (oral tablet) | Drug | 10 mg |
Primary outcome
Incidence of adverse events
Time frame: From start of investigational drug administration to final test and observation; up to approximately 1 year
To evaluate the Long-term safety of TS-142 in patients with insomnia
5 secondary outcomes
Mean change from baseline of subjective sleep latency (sSL)
Time frame: From baseline up to Week 52
Mean change from baseline of subjective sleep efficacy (sSE)
Time frame: From baseline up to Week 52
Mean change from baseline of subjective total sleep time (sTST)
Time frame: From baseline up to Week 52
Mean change from baseline of subjective wake time after sleep onset (sWASO)
Time frame: From baseline up to Week 52
Mean change from baseline of subjective number of awakenings (sNAW)
Time frame: From baseline up to Week 52
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Patients with Insomnia
Enrolling by invitation
Acute Psychological Sleep Stabilisation for Patients Hospitalised With Depression
Insomnia, Depression
Recruiting
Perioperative Meditation Music Intervention in Patients With Type 2 Diabetes Undergoing Elective Surgery
Diabetes Type 2
RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
Not yet recruiting
Effects of Connective Tissue Massage in Patients With Chronic Insomnia
Chronic Insomnia
Not yet recruiting
Comparative Effects of Dynamic Cupping and Facilitated Positional Release in Cervicogenic Headache
Cervicogenic Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Taisho Director study director
Taisho Pharmaceutical Co., Ltd.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing TS-142 5 mg and TS-142 10 mg in people with Patients with Insomnia, run by Taisho Pharmaceutical Co., Ltd. at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events (time frame: From start of investigational drug administration to final test and observation; up to approximately 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2025.